Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: Candidates for grass pollen-specific immunotherapy

European Journal of Immunology

Volumn 32, Issue 1, 2002, Pages 270-280

  Swoboda, Ines ^a   De Weerd, Nicole ^a   Bhalla, Prem L ^a   Niederberger, Verena ^b   Sperr, W R ^b   Valent, Peter ^b   Kahlert, Helga ^c   Fiebig, Helmut ^c   Verdino, Petra ^d   Keller, Walter ^d   Ebner, Christof ^b   Spitzauer, Susanne ^b   Valenta, Rudolf ^b   Singh, Mohan B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF VIENNA   (Austria)

^c ALLERGOPHARMA JOACHIM GANZER KG   (Germany)

^d Institute of Chemistry   (Austria)

Author keywords

Allergen engineering; Grass; Hypoallergenic; Immunotherapy; Pollen allergen

Indexed keywords

HISTAMINE; IMMUNOGLOBULIN E; POLLEN ANTIGEN; VACCINE;

ALLERGENICITY; ARTICLE; B LYMPHOCYTE; BASOPHIL; CELL CLONE; CELL LINE; CELL PROLIFERATION; CIRCULAR DICHROISM; CONTROLLED STUDY; EPITOPE MAPPING; GRASS POLLEN; HISTAMINE RELEASE; HUMAN; IMMUNOTHERAPY; MUTANT; NONHUMAN; POINT MUTATION; POLLEN ALLERGY; PRICK TEST; PRIORITY JOURNAL; PROTEIN BINDING; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; T LYMPHOCYTE; WILD TYPE;

ALLERGENS; AMINO ACID SEQUENCE; AMINO ACIDS; BASOPHILS; BINDING SITES; CELL DIVISION; CLONE CELLS; CONSERVED SEQUENCE; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HISTAMINE RELEASE; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOTHERAPY, ACTIVE; LOLIUM; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PLANT PROTEINS; POLLEN; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; RECOMBINATION, GENETIC; SKIN;

EID: 0036149973     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X     Document Type: Article

References (32)

1. Increased prevalence of pollen allergy in Japan
2. Allergen Immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper
3. Immunologic changes associated with allergen immunotherapy
4. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clone specific for Phl p 1, a major grass pollen allergen
5. Induction of antibody responses to new B-cell epitopes indicates vaccination character of allergen immunotherapy
6. Conversion of the major birch pollen allergen, Bet v 1 to two non-anaphylactic T-cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy
7. Mapping of the antigenic epitopes of Lol p VB using gene fragmentation
8. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: Contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2
9. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy
10. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy
11. Isolation of cDNA encoding newly identified major allergenic protein of ryegrass pollen: Intracellular targeting to the amyloplast
12. Cloning of a cDNA encoding a group-V (group-IX) allergen isoform from ryegrass pollen that demonstrates specific antigenic immunoreactivity
13. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl p V allergen
14. IgE antibodies to recombinant pollen allergens (Phi p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE
15. Mapping of the antigenic epitopes of Lol p VB using gene fragmentation
16. Molecular basis of IgE-recognition of Lol p 5, a major allergen of ryegrass pollen
17. Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen
18. PHD: Predicting one dimensional protein structure by profile-based neural networks
19. Prediction of protein secondary structure at better than 70% accuracy
20. "Allergen engineering": Variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity
21. T-cell responses to allergens: Epitope specificity and clinical relevance
22. The use of peptides for allergy immunotherapy
23. The receptor with high affinity for immunoglobin E
24. T-cell receptor gene diversity and selection
25. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation
26. Fel d 1 peptides: Effects on skin tests and cytokine synthesis in cat-allergic human subjects
27. An immunogenic analysis of the T-cell recognition of the major house dust mite allergen Der p II: Identification of high and low-responder HLA-DQ alleles and localization of T-cell epitopes
28. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens
29. Calculation of protein conformation from circular dichroism
30. Interleukin 3 activates human blood basophils via high-affinity binding sites
31. Skin-prick test
32. Reactivity of T-cells with grass pollen extract and allergoid